血糖檢查和糖尿病管理

血糖檢查和糖尿病管理 是由出版商Trimark Publications在2009年04月所出版的。 這份英文市場調查報告書包含366 pages 價格從美金3400起跳。

目錄

Abstract

There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes, particularly Type 2 diabetes, among adults across the world. As such, the global market for blood glucose testing products is undergoing a significant transition driven by the advent of new analytical technologies and developments in diabetes treatment. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, certain segments of the market, such as home testing devices for diabetes management, will exhibit strong growth. What' s more, non-invasive testing now represents a major new area for the application of IVD testing. Additionally, direct access testing--or over-the-counter testing, which allows consumers to order tests themselves without visiting a doctor--has emerged as a strong force in the blood glucose testing segment.

The purpose of this TriMark Publications report is to describe the specific market segments for blood glucose testing and diabetes management. This study reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum or plasma or whole-blood glucose concentrations. Moreover, it examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctor' s offices and at-home care locations.

Table of Contents

1. Overview

• 1.1 Statement of Report
• 1.2 About this Report
• 1.3 Scope of the Report
• 1.4 Methodology
• 1.5 Executive Summary

2. Diabetes

• 2.1 Demographics of Diabetes
  • 2.1.1 Worldwide Diabetes Incidence
  • 2.1.2 Diabetes in the U.S.
• 2.2 Economics of Diabetes
• 2.3 Understanding the Metabolic Conditions Underlying and Associated with Diabetes
  • 2.3.1 Pre-Diabetes Syndrome
  • 2.3.2 Metabolic Syndrome
  • 2.3.3 Diabetes and Inflammation
  • 2.3.4 Progression of Diabetes
  • 2.3.5 Complications and Co-Morbidities in Type 2 Diabetes
  • 2.3.6 Hypoglycemia and Treatment
  • 2.3.7 Risk Factors and Diabetes
  • 2.3.8 Cardiovascular Disease Facts
• 2.4 Glucose Control in Diabetic Patients
• 2.5 Tight Glucose Control in Treating Diabetes
• 2.6 Glucose Monitoring Devices
  • 2.6.1 Key Issues Identified for Glucose Monitoring
  • 2.6.2 Device Description
  • 2.6.3 Precision
  • 2.6.4 Limitations of Existing Glucose Monitoring Products

3. Glucose Measurements

• 3.1 Glucose Monitoring Markets
  • 3.1.1 Overview of Market Segments
    • 3.1.1.1 Over-the-Counter (OTC) Self-Testing Glucose Market
    • 3.1.1.2 Professional Glucose Testing Market
  • 3.1.2 Market Analysis: Size, Growth, Share and Competitors
    • 3.1.2.1 Worldwide Market
    • 3.1.2.2 U.S. Market
    • 3.1.2.3 European Market
    • 3.1.2.4 Asian Market
• 3.2 Glucose Analytical Test Methods
  • 3.2.1 Glucose Oxidase
  • 3.2.2 Glucose Hexokinase
  • 3.2.3 Glucose Dehydrogenase Pyrroloquinoline quinone (GDH-PQQ)
  • 3.2.4 Amperometric Biosensors
  • 3.2.5 Interfering Substances
  • 3.2.6 Monitoring HbA1c Levels
  • 3.2.7 Quality Control Criteria
• 3.3 Reagents and Equipment
  • 3.3.1 Lancets
  • 3.3.2 Blood Glucose Test Kit
  • 3.3.3 Blood Glucose Monitor and Insulin Doser
  • 3.3.4 Diabetes Tracking System
  • 3.3.5 Blood Glucose Sensors
  • 3.3.6 Blood Glucose Reagent Test Strips
  • 3.3.7 Control Solutions and Calibrators
  • 3.3.8 Sharps Devices
  • 3.3.9 Needle Destruction Devices
  • 3.3.10 Urine Strips
  • 3.3.11 Blood Ketone Testing
  • 3.3.12 Voice Operated Glucose Meters
• 3.4 Glucose Meters
  • 3.4.1 LifeScan
  • 3.4.2 Roche Accu-Chek
  • 3.4.3 Bayer
  • 3.4.4 Abbott
  • 3.4.5 Acon Laboratories
  • 3.4.6 Quest Diagnostics Company
  • 3.4.7 Agamatrix
  • 3.4.8 AiMedics
  • 3.4.9 Apex Biotechnology
  • 3.4.10 77 Elektronika
  • 3.4.11 Arkray
  • 3.4.12 Accurex
  • 3.4.13 Axis-Shield
  • 3.4.14 Home Diagnostics
  • 3.4.15 Hypoguard
  • 3.4.16 Metrika
  • 3.4.17 Biopeak
  • 3.4.18 BioTex
  • 3.4.19 Integrity Applications
  • 3.4.20 Calisto Medical
  • 3.4.21 Allmedicus
  • 3.4.22 Diabetech
  • 3.4.23 Diagnostic Devices
  • 3.4.24 DIRAmed
  • 3.4.25 Entelos
  • 3.4.26 Fifty50 Pharmacy
  • 3.4.27 Fluent Biomedical
  • 3.4.28 GenExel-Sein
  • 3.4.29 GlucoLight
  • 3.4.30 GluMetrics
  • 3.4.31 Glucoplus
  • 3.4.32 GlySens
  • 3.4.33 HMD BioMedical
  • 3.4.34 InLight Solutions
  • 3.4.35 Insulet
  • 3.4.36 IntelliDx
  • 3.4.37 Kumetrix
  • 3.4.38 Lein Applied Diagnostics
  • 3.4.39 Cholestech
  • 3.4.40 LighTouch Medical
  • 3.4.41 LG Electronics
  • 3.4.42 Luminous Medical
  • 3.4.43 Menarini Diagnostics
  • 3.4.44 OrSense
  • 3.4.45 Pelikan Technologies
  • 3.4.46 Polymer Technology Systems
  • 3.4.47 PreciSense
  • 3.4.48 Sensys Medical
  • 3.4.49 Smiths Medical MD
  • 3.4.50 TaiDoc Technology
  • 3.4.51 U.S. Diagnostics
  • 3.4.52 VeraLight
  • 3.4.53 Zyvex
  • 3.4.54 Health Hero Network
  • 3.4.55 IN4 Technology
  • 3.4.56 Nipro
  • 3.4.57 Teco Diagnostics
  • 3.4.58 Uchain Industrial
  • 3.4.59 GlucoStats System
  • 3.4.60 Sanko Junyaku
  • 3.4.61 International Technidyne
  • 3.4.62 Medtronic MiniMed
  • 3.4.63 Diacare
  • 3.4.64 Tyson Bioresearch
  • 3.4.65 Bionime
  • 3.4.66 Home Diagnostics
  • 3.4.67 BTNX
  • 3.5 Diagnosing Diabetes Using In Vitro Laboratory Tests
  • 3.5.1 New Diagnostic Guidelines
  • 3.5.2 Fasting Plasma Glucose (FPG) Test
  • 3.5.3 Glucose Tolerance Test
  • 3.5.4 Test for Glycosylated Hemoglobin
  • 3.5.5 Fructosamine
  • 3.5.6 Combined Self-Testing Glucose Monitor with Insulin Delivery
• 3.6 Continuous and Non-invasive Glucose Patient Monitoring
  • 3.6.1 Medtronic MiniMed Continuous Glucose Monitoring System
  • 3.6.2 Cygnus GlucoWatch Biographer
  • 3.6.3 Abbott FreeStyle Continuous Glucose Monitor System
  • 3.6.4 DexCom, Inc. STS Continuous Glucose Monitoring System
  • 3.6.5 Echo Therapeutics
  • 3.6.6 Sensors for Medicine and Science
  • 3.6.7 New Developments in Glucose Monitors
  • 3.6.8 Strategies for Developing Non-invasive Continuous Glucose Monitoring
• 3.7 Glycosylated Hemoglobin Glucose Monitoring
• 3.8 Clinical Laboratory Instruments
  • 3.8.1 Ultra-Large Throughput Chemistry Analyzers Large-Throughput Analyzers
  • 3.8.2 Large-Throughput Analyzers
  • 3.8.3 Mid-Size Clinical Chemistry Analyzers
  • 3.8.4 Chemistry Analyzers for the Small Volume Market

4. Business Trends in Glucose Testing

• 4.1 Expanding Opportunities in Blood Glucose Monitoring Market
• 4.2 Home Diabetes Test Kits an Evolving Market
• 4.3 Competitive Strategies
• 4.4 Analyses of the Current Market Conditions, Competition and Product Mix
• 4.5 The New Paradigm
• 4.6 Mergers of Diagnostic Companies
• 4.7 Healthcare Cost Controls
• 4.8 Competition for Services
• 4.9 Drivers of Clinical Glucose Testing
• 4.10 Confluence of New Technology
• 4.11 Trends in Reimbursement Practices
• 4.12 Managed Care
• 4.13 Changes in Patient Management
• 4.14 Satellite Facilities
• 4.15 Point-of-Care Testing
• 4.16 Regionalization of Laboratory Care
• 4.17 Drivers of the Point of Care Testing Sector
• 4.18 Diagnostic Testing Growth Trends
• 4.19 PIPE Financing
• 4.20 Brand Loyalty
• 4.21 Insurance Coverage a Key Factor
• 4.22 Medicare Coverage
• 4.23 Products at Competitive Price Points
• 4.24 Drugstores Critical to the Diabetic Care Category
• 4.25 Drugstore Chains Increasingly Running Diabetes Care Programs
• 4.26 Co-branding Strategies

5. Important Technology Trends

• 5.1 Biosensor Technology
• 5.2 Data Management
  • 5.2.1 Information Management Advances
  • 5.2.2 Patient Care Information System Strategy
  • 5.2.3 Connectivity Platforms
    • 5.2.3.1 DataLink Data Management System
    • 5.2.3.2 RALS-Plus
    • 5.2.3.3 LabPortal.com
    • 5.2.3.4 LifeScan Electronic Data Interfaces
    • 5.2.3.5 Computer Software for Home Glucose Meters
    • 5.2.3.6 Health Buddy Systems Monitoring Technologies
    • 5.2.3.7 Medtronic' s MiniMed Paradigm Glucose Meter
  • 5.2.4 POL Laboratory Data Management
    • 5.2.4.1 Electronic Medical Record Systems and Physician Office Laboratory Data Linking Software
    • 5.2.4.2 Physician Office Laboratory Data Linking Software and Interface to the Laboratory Information System
  • 5.2.5 Technical Problems of Connectivity
  • 5.2.6 Web-based Data Interface
  • 5.2.7 HIT Competition
  • 5.2.8 FDA Required Software Verification
• 5.3 Advantages of Connectivity
• 5.4 Home Care Analysis
  • 5.4.1 Remote Patient Monitoring
• 5.5 Technology Platform Innovations in Glucose Testing
• 5.6 Move Away from Central Laboratory
• 5.7 Trends in Detection and Diagnosis
  • 5.7.1 Minimally-Invasive Devices
  • 5.7.2 Non-invasive Devices Future Developments and Market Strategy
  • 5.7.3 Continuous Test Systems and the Future of Integrated Glucose/Insulin Delivery

6. Competitive Analysis of the Glucose Testing Markets

• 6.1 The Market Players
• 6.2 Device Categories
• 6.3 Range of Products
  • 6.3.1 Cost of Testing
  • 6.3.2 Sample Size Required
  • 6.3.3 Sampling Other Areas
  • 6.3.4 Time Until Patient Obtains Results
  • 6.3.5 Enclosed Test Strips
  • 6.3.6 Test Strip Calibration
  • 6.3.7 Lancing Devices
• 6.4 Data Handling
• 6.5 New Developments
• 6.6 Marketing New Features
• 6.7 Test Strip Sales
• 6.8 Reimbursement
• 6.9 Market Demand and Composition
• 6.10 Product Mix
  • 6.10.1 LifeScan
  • 6.10.2 Roche Diagnostics
  • 6.10.3 Bayer Diagnostics
  • 6.10.4 Abbott (MediSense)
  • 6.10.5 Other Players
    • 6.10.5.1 Hemocue
    • 6.10.5.2 Home Diagnostics, Inc.
    • 6.10.5.3 ArkRay Hypoguard
    • 6.10.5.4 Polymer Technology Systems, Inc.
    • 6.10.5.5 QuestStar Medical, Inc.
• 6.11 Devices that Measure Glycohemoglobin
• 6.12 Market Drivers and Restraints
• 6.13 Market and Product Trends
• 6.14 Increased Market Penetration
• 6.15 Costs of Doing Business in Europe
• 6.16 Drivers of European Diagnostics Testing
• 6.17 European Reimbursement Practices
• 6.18 Cost Containment in Europe
• 6.19 Market Overview of Glucose Monitoring
  • 6.19.1 U.S. Market Segment
  • 6.19.2 European Market
  • 6.19.3 Japanese Market
• 6.20 Competitive Strategies
• 6.21 Price Competition
• 6.22 Analyses of the Current Market Conditions, Competition and Product Mix
  • 6.22.1 First-Generation Monitors
  • 6.22.2 Second-Generation Monitors
  • 6.22.3 Third-Generation SMBG Technologies
• 6.23 Design of Glucose Testing Devices
• 6.24 Insulin Delivery Devices
• 6.25 Key Glucose Testing Sector Developments
• 6.26 Important M&A Activity
• 6.27 Product Launches

7. Government Regulation of Medical Devices

• 7.1 U.S. Regulations
  • 7.1.1 Importing Medical Devices into the U.S.
  • 7.1.2 Exporting Medical Devices from the U.S.
• 7.2 U.K. Regulations
• 7.3 E.U. Regulations
• 7.4 French Regulations
• 7.5 Japanese Regulations
• 7.6 Korean Regulations
• 7.7 China Regulations
• 7.8 FDA Regulations and Recalls
• 7.9 Legal Liability for Glucose Meters
• 7.10 ISO 9000 Quality System
• 7.11 Recent Regulatory Approvals
• 7.12 FDA Labeling Requirements

8. Corporate Profiles

• 8.1 Abbott Laboratories
• 8.2 Accurex Biomedical
• 8.3 Acon Laboratories
• 8.4 AgaMatrix
• 8.5 AiMedics
• 8.6 Apex Biotechnology
• 8.7 Axis-Shield
• 8.8 Bayer
• 8.9 Biopeak Corporation
• 8.10 BioTex
• 8.11 Calisto Medical
• 8.12 Cybermedical
• 8.13 DexCom
• 8.14 Diabetech
• 8.15 DIRAmed
• 8.16 Echo Therapeutics
• 8.17 Entelos
• 8.18 Fora Care
• 8.19 Glucoplus
• 8.20 77 Elektronika
• 8.21 Flexsite Diagnostics
• 8.22 GenExel-Sein
• 8.23 GlucoLight
• 8.24 GluMetrics
• 8.25 GlySens
• 8.26 Hemocue
• 8.27 Home Diagnostics
• 8.28 HTL Strefa
• 8.29 Hypoguard
• 8.30 IN4 Technology
• 8.31 InLight Solutions
• 8.32 International Technidyne
• 8.33 Insulet
• 8.34 IntelliDx
• 8.35 Lein Applied Diagnostics
• 8.36 LifeScan
• 8.37 Luminous Medical
• 8.38 Medtronic
• 8.39 Menarini Diagnostics
• 8.40 Newton Photonics
• 8.41 Nipro Medical
• 8.42 OrSense
• 8.43 Panasonic Shikoku Electronics
• 8.44 Pelikan Technologies
• 8.45 Polymer Technology Systems
• 8.46 PreciSense
• 8.47 Roche Diagnostics
• 8.48 Sanko Junyaku
• 8.49 Sanwa Kagaku Kenkyusho
• 8.50 Sensys Medical
• 8.51 Solianis Holding
• 8.52 SurgiLance
• 8.53 Smiths Medical MD
• 8.54 SpectRx
• 8.55 Taidoc Technology
• 8.56 Teco Diagnostics
• 8.57 U.S. Diagnostics
• 8.58 VeraLight
• 8.59 Ypsomed Holding
• 8.60 Zyvex

Appendix

• Appendix 1: Contact Information for Companies Profiled
• Appendix 2: List of Competitors for Glucose Test Meters and Equipment
• Appendix 3: FDA Proprietary Devices for Measuring Blood Glucose
• Appendix 4: Overview of FDA Device Regulations
• Appendix 5: Retail Prices of Glucose Meters
• Appendix 6: Glucose Meters: Components, Design, Sources
• Appendix 7: Pharmaceutical Sampling Practices

INDEX OF FIGURES

• Figure 2.1: Worldwide Rates of Diabetes Cases, 2000-2025
• Figure 2.2: Prevalence of Diabetes by Age in the U.S., 2007
• Figure 2.3: New Cases of Diabetes Diagnosed in the U.S. Adult Population, 2007
• Figure 2.4: Rate of New Diabetes Cases among Children in the U.S., 2007
• Figure 2.5: Diabetes Death Rate by Race and Sex in the U.S., 1979-2006
• Figure 2.6: Annual Death Rate of U.S. Population from Heart Disease, 1950-2008
• Figure 2.7: How Diabetes Dollars Are Spent in the U.S., 2007
• Figure 2.8: Percentage Breakdown of U.S. Healthcare Spending, 2008
• Figure 2.9: Percentage of U.S. Population that is Overweight, 1976-2004
• Figure 2.10: Hypertension Drugs Newly Prescribed or Continued in the U.S., 1994-2007
• Figure 3.1: Glucose Self-Monitoring Market Share by Geographical Region, 2007
• Figure 3.2: Share of the U.S. Self-Testing Diagnostic Market, 2008
• Figure 3.3: Domestic Manufacturers' Share of Chinese Glucose Meter Market, 2007
• Figure 3.4: Personal Lancet Unit Sales Market Share by Geographic Region, 2008
• Figure 3.5: Estimated U.S. Inpatient Volume, 2008

INDEX OF TABLES

• Table 2.1: Normal Glucose Values-Fasting State
• Table 2.2: Countries with the Largest Numbers of Diabetics, 2007 and 2025
• Table 2.3: U.S. Population of Diabetics (Diagnosed and Undiagnosed) by Ethnic Group, 2007
• Table 2.4: Healthcare Utilization by Diabetic Patients, 2006
• Table 2.5: Cost of Diabetes in the U.S., 2007
• Table 2.6: Ten Leading Diagnoses for Co-morbid Chronic Diseases in the U.S., by Percentage of Patient Visits, 2006
• Table 2.7: U.S. Incidence of Diagnosed Diabetes by Age, 2006
• Table 2.8: Prevalence and Financial Burden of Major Diseases in the U.S., 2007
• Table 2.9: Top Twelve Causes of Death in the U.S., 2006
• Table 2.10: Death Rate from Cardiovascular Diseases by Country, 2008
• Table 2.11: Life Expectancy Rate by Country, 2008
• Table 2.12: Per-Event Costs of Diabetes Complications
• Table 2.13: Odds Ratio of Progression to Complications Associated With Type 2 Diabetes
• Table 2.14: Prevalence of Complications among Patients with Diabetes
• Table 2.15: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus
• Table 2.16: Average Years Gained Free of Diabetes-Related Disease with Intensive Management
• Table 2.17: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases and Stroke in the U.S., 2008
• Table 2.18: Worldwide Market for Cardiac Care Therapeutics, 2003-2010
• Table 2.19: Top 20 Drugs for 2007 by U.S. Sales
• Table 2.20: Major Causes of End-Stage Renal Disease
• Table 2.21: Key Features Considered for Glucose Meter Devices
• Table 3.1: Laboratory Assessment of Diabetic Vascular Disease
• Table 3.2: Key Market Drivers for Glucose Testing
• Table 3.3: Key Aspects of Professional Glucose Testing
• Table 3.4: Demographic Characteristics Home Testing Kit Buyers
• Table 3.5: Top Brand Preferences for Home Glucose Testing Kits
• Table 3.6: Instances When Patients Prefer Professional Glucose Testing
• Table 3.7: Advantages of a Home Testing Kit
• Table 3.8: Disadvantages of Using a Home Testing Kit
• Table 3.9: Popular Shopping Destinations for Buying or Seeking Information on Home Testing Kits
• Table 3.10: Total Global Professional Glucose Testing Market, 2007-2012
• Table 3.11: Worldwide Glucose Self-Testing Market Sales (Meters, Strips, Lancets), 2004-2012
• Table 3.12: Percentage of GDP Healthcare Spending by Country, 2008
• Table 3.13: Worldwide Glucose Market for Self-Testing Sales (Meters and Strips), 2004-2012
• Table 3.14: U.S. Blood Glucose Reagent Strip Market, 2004-2013
• Table 3.15: U.S. Sales for OTC Blood Glucose Meters and Strips, 2007
• Table 3.16: Top Four Players in the U.S. Blood Glucose Strips Market (Ranked by % Sales), 2008
• Table 3.17: European Glucose Self-Testing Market (Meters, Strips, Lancets), 2003-2012
• Table 3.18: Asian Glucose Self-Testing Market (Meters, Strips, Lancets), 2000-2012
• Table 3.19: Japanese Glucose Self-Testing Market (Meters, Strips, Lancets), 2000-2012
• Table 3.20: Chinese Glucose Self-Testing (Meters, Strips, Lancets) Market and Professional POC Devices, 2000-2012
• Table 3.21: China Blood Glucose Reagent Strip Market, 2000-2012
• Table 3.22: Indian IVD Market, 2006-2012
• Table 3.23: Number of Clinical Labs in India, 2008
• Table 3.24: Indian IVD Market Sectors and Market Share, 2006
• Table 3.25: Indian Glucose Self-Testing Market (Meters, Strips, Lancets), 2000-2012
• Table 3.26: Indian Blood Glucose Reagent Strip Market, 2000-2012
• Table 3.27: Top Domestic IVD Companies in India
• Table 3.28: Leading Global IVD Companies in India, 2008
• Table 3.29: BRIC countries, Percentage of GDP Spent on Healthcare, 2008
• Table 3.30: ROW Glucose Self-Testing Market (Meters, Strips, Lancets), 2000-2012
• Table 3.31: Global Unit Sales of Home care Lancets, 2006-2012
• Table 3.32: Dollar Sales of Lancets in the U.S., 2000-2012
• Table 3.33: Dollar Sales of Lancets in the E.U., 2000-2012
• Table 3.34: Unit Sales of Homecare Glucose Self-testing Lancets in the U.S., 2000-2012
• Table 3.35: Unit Sales of Homecare Glucose Self-testing Lancets in the E.U., 2000-2012
• Table 3.36: Competition in the Lancet Market Segment
• Table 3.37: Currently Available Lancing Devices and Lancets
• Table 3.38: Customer Priorities- Glucose Meter Self-Testing Market, 2001-2012
• Table 3.39: Current Blood Glucose Meters: Pricing, Sample Size, Features
• Table 3.40: Technology of Glucose Testing Instruments
• Table 3.41: Key Features of Reagent Test Strips
• Table 3.42: Limitations of Urine Glucose Monitoring
• Table 3.43: Advantages of Urine Glucose Monitoring
• Table 3.44: Blood Ketone Reading Indications
• Table 3.45: Accu-Chek Blood Glucose Monitoring Systems
• Table 3.46: GlucoTrack Comparison and Results
• Table 3.47: Home Diagnostics' Current Product Portfolio
• Table 3.48: Detailed Features of Selected CGM Systems Currently Available
• Table 3.49: Relationship of A1C to Average Whole Blood and Plasma Glucose Levels
• Table 3.50: Distributors of Glucose Meters
• Table 3.51: Ultra-Large Clinical Chemistry Analyzers
• Table 3.52: JEOL Analyzer Comparison
• Table 3.53: Large Clinical Chemistry Analyzers
• Table 3.54: Mid-size Clinical Chemistry Analyzers
• Table 3.55: Small Clinical Chemistry Analyzers
• Table 4.1: Medicare Billing Guidelines for Multichannel Chemistry Tests
• Table 5.1: Customized Reports Must Support CAP and JCAHO Requirements
• Table 5.2: Applications of RALS Connectivity with POCT Devices
• Table 6.1: Comparisons of Blood Glucose Monitoring Systems
• Table 6.2: Major Lancing Devices on the Market
• Table 6.3: Glucose Meters Offering Data Management
• Table 6.4: Comparison of A1C Home Test Kits.
• Table 6.5: Unit Costs of Glucose-Monitoring Supplies in the U.K.
• Table 6.6: Annual Costs of SMBG in the U.K.
• Table 6.7: Syringes for Administering Insulin
• Table 6.8: Insulin Pens
• Table 6.9: Injection Aids
• Table 6.10: Jet Injectors
• Table 6.11: External Insulin Pumps
• Table 6.12: Status of Inhaled Insulin Products, 2009
• Table 6.13: Insulin Delivery Device Market, 2004-2014
• Table 7.1: Leading Global Medical Device Companies, 2007
• Table 7.2: Imports of U.S. Medical Devices to Japan, 2005-2007
• Table 8.1: Products Marketed by Abbott in the Diagnostic Market
• Table 8.2: Key Roche Diagnostic Products
• Table A1.1: Company Headquarters Contact Information
• Table A2.1: Glucose Meters and Equipment' List of Manufacturers and Suppliers
• Table A3.1: Detailed Information on Available Glucose Meters
• Table A5.1: Glucose Meters' Pricing
• Table A6.1: Contract Manufacturers for Glucose Meter Components
• Table A6.2: ASIC manufacturers

相關商品

病患監測相關市場調查報告書

金磚5國各國(巴西、俄羅斯、印度、中國、南非)的非侵入式血壓計市場預測(∼2017年)
Non-Invasive Blood Pressure Monitors Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
價格 : US $ 2500
出版日期 : 2012年01月

金磚5國各國(巴西、俄羅斯、印度、中國、南非)的病患監護用配件市場預測(∼2017年)
Patient Monitoring Accessories (Patient Monitoring Leads and Electrodes, Non-Invasive Blood Pressure Cuffs and Patient Monitoring Temperature Probes) Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
價格 : US $ 2500
出版日期 : 2012年01月

全球連續式血糖監測系統(CGM)系統市場:開發平台分析，競爭環境，到2017年為止的市場預測
Continuous Glucose Monitoring (CGM) Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
價格 : US $ 3995
出版日期 : 2012年01月

Trimark Publications發行的醫療設備相關市場調查報告書

心臟標誌物診斷測試市場

Cardiac Marker Diagnostic Testing Markets

價格 : US $ 3400

出版日期 : 2011年11月

臨床實驗室之質譜分析

Mass Spectroscopy for Clinical Laboratory Analysis

價格 : US $ 3400

出版日期 : 2011年11月

定點醫療診斷檢査動向

Point of Care Diagnostic Testing Sector Trends

價格 : US $ 3400

出版日期 : 2011年11月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!